Trial Profile
A phase I randomized dose-seeking trial of PCK3145 in asymptomatic, castrate metastatic prostate cancer patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Tigapotide (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- 11 Jun 2008 The expected completion date for this trial is 1 Mar 2009 as reported by ClinicalTrials.gov.
- 01 Dec 2005 New trial record.